NCT01946074 is a Phase 1 clinical trial of paclitaxel in Advanced Solid Tumors, sponsored by AbbVie.

Who is sponsoring NCT01946074?

NCT01946074 is sponsored by AbbVie.

What drugs are being tested in NCT01946074?

Interventions in NCT01946074: paclitaxel, FOLFIRI, ABT-165, ABBV-181.

What condition does NCT01946074 study?

NCT01946074 studies Advanced Solid Tumors.

Is NCT01946074 still recruiting?

NCT01946074 is currently completed. Last updated 15 December 2023.

Last reviewed 2023-12-15 · How we verify

NCT01946074

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of ABT-165 in Subjects With Solid Tumors

Completed Phase 1 Last updated 15 December 2023

What this trial tests

Phase 1 trial testing paclitaxel in Advanced Solid Tumors in 101 participants. Completed in 28 September 2022.

Timeline

8 August 2013

Primary endpoint
28 September 2022

28 September 2022

Quick facts

Lead sponsor	AbbVie
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	101
Start date	8 August 2013
Primary completion	28 September 2022
Estimated completion	28 September 2022
Sites	10 locations across United States

Drugs / interventions tested

paclitaxel — full drug profile →
FOLFIRI (folfiri) — full drug profile →
ABT-165 — full drug profile →
ABBV-181 — full drug profile →

Conditions studied

Advanced Solid Tumors — all drugs for Advanced Solid Tumors →

Sponsor

AbbVie — full company profile →

Who can join

Adults 18 to 99, any sex, with Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABT-165 when administered as monotherapy and in combination with paclitaxel or 5-fluoruracil, folinic acid and irinotecan (FOLFIRI) or ABBV-181 with/without paclitaxel in subjects with advanced solid tumors. Enrollment to Cohorts A, B were completed and for Cohorts C and D are recruiting.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Emerging new therapeutic antibody derivatives for cancer treatment.
Jin S, Sun Y, Liang X, Gu X, et al · · 2022 · cited 304× · PMID 35132063 · DOI 10.1038/s41392-021-00868-x
Targeting the Notch Signaling Pathway in Chronic Inflammatory Diseases.
Christopoulos PF, Gjølberg TT, Krüger S, Haraldsen G, et al · · 2021 · cited 86× · PMID 33912195 · DOI 10.3389/fimmu.2021.668207
Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies.
Husain B, Ellerman D. · · 2018 · cited 83× · PMID 30132211 · DOI 10.1007/s40259-018-0299-9
Biology drives the discovery of bispecific antibodies as innovative therapeutics.
Nie S, Wang Z, Moscoso-Castro M, D'Souza P, et al · · 2020 · cited 79× · PMID 33928225 · DOI 10.1093/abt/tbaa003
Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer.
Elshiaty M, Schindler H, Christopoulos P. · · 2021 · cited 71× · PMID 34073188 · DOI 10.3390/ijms22115632
Therapeutic Targeting of Notch Signaling: From Cancer to Inflammatory Disorders.
Allen F, Maillard I. · · 2021 · cited 62× · PMID 34124039 · DOI 10.3389/fcell.2021.649205
Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies.
You G, Won J, Lee Y, Moon D, et al · · 2021 · cited 39× · PMID 34358141 · DOI 10.3390/vaccines9070724
Targeting Notch to Maximize Chemotherapeutic Benefits: Rationale, Advanced Strategies, and Future Perspectives.
Zhdanovskaya N, Firrincieli M, Lazzari S, Lazzari S, et al · · 2021 · cited 28× · PMID 34680255 · DOI 10.3390/cancers13205106

Verify or expand the search:

Other trials of paclitaxel

Trials testing the same drug.

NCT06694454 — Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immun · Phase 1, PHASE2 · not yet recruiting
NCT07407452 — Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Che · Phase 2 · not yet recruiting
NCT06584032 — Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer · Phase 3 · recruiting
NCT05904379 — AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer · Phase 1, PHASE2 · active not recruiting
NCT05834348 — A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in N · completed

Other recruiting trials for Advanced Solid Tumors

Currently open trials in the same condition.

NCT07504445 — Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07589530 — Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other AbbVie trials

Trials by the same sponsor.

NCT07219017 — A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Participants · Phase 1 · completed
NCT05316220 — A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years W · Phase 3 · withdrawn
NCT07024797 — Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult · Phase 1 · completed
NCT07058051 — Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in China · completed
NCT07007091 — A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01946074 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AbbVie
Last refreshed: 15 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01946074.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing